Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients

Table 1 Baseline characteristics of the study population and immunosuppression before conversion to everolimus (n = 222)

	n (%)	Mean ± SD
Recipient age (yr)	-	53 ± 10.5
Sex
Male	189 (85%)	-
Female	33 (15%)	-
Mean time from transplant to conversion (yr)	-	8.1 ± 4.5
Type of transplant
First transplant	215 (96.7%)	-
Re-transplant	6 (2.8%)	-
Multiorgan transplant	1 (0.4%)	-
Reasons for transplanta
Ischaemic myocardiopathy	114 (51%)	-
Dilated myocardiopathy	74 (33%)	-
Valve disease	14 (6%)	-
Othersb	16 (7%)	-
Donor age (yr)	-	32.2 ± 12.7
Donor positive for CMV serologyd	106 (48%)	-
Recipient positive for CMV serologye	155 (70%)	-
Pre-transplant risk factorsc	139 (63%)	-
Arterial hypertension	55 (25%)	-
Diabetes	36 (16%)	-
Renal failure	4 (2%)	-
Osteoporosis	3 (1%)	-
Hypercholesterolaemia	29 (13%)	-
Dyslipidaemia	29 (13%)	-
Smoking	23 (10%)	-
Baseline immunosuppression
CNI	210 (95%)	-
CsA	152 (72%)	-
Dose, mg/d	-	142.3 ± 51.6
Blood levels, ng/mL	-	126.1 ± 50.9
Tacrolimus	58 (28%)	-
Dose, mg/d	-	2.9 ± 1.8
Blood levels, ng/mL	-	8.3 ± 4.0
Antimetabolite	189 (85%)	-
MMF	143 (76%)	-
Dose, mg/d	-	1.446.1 ± 499.0
Blood levels, ng/mL	-	2.9 ± 1.7
MFS	8 (4%)	-
Dose, mg/d	-	742.5 ± 413.1
Blood levels, ng/mL	-	3.8 ± 1.7
Azathioprine	38 (20%)	-
Dose, mg/d	-	84.9 ± 46.5
Blood levels, ng/mL	-	-
Corticosteroids	154 (69%)	-
Dose, mg/d	-	5.2 ± 4.2
SRL	21 (9%)	-
Dose, mg/d	-	5.8 ± 2.5

SD: Standard deviation; CMV: Cytomegalovirus; CNI: Calcineurin inhibitor; CsA: Cyclosporine; SRL: Sirolimus; MFS: Mycophenolate sodium; MMF: Mycophenolate mofetil;

^aNot available in 4 patients;

^bCongenital defects, hypertrophic myocardiopathy and acute myocarditis in two patients each, the rest in only one patient;

^cPatient may present multiple risk factors;

^dNot known in 44 patients;

^eNot known in 28 patients.